Search research articles
Contact Us
Filters
Showing results (51-60 of 118) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2020
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Suparna Wedam, Lola Fashoyin-Aje, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2022
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor
Vaibhav Kumar, Leslie Doros, Margaret Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
Preeti Narayan, Asma Dilawari, Christy Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
Mirat Shah, Christy L Osgood, Anup K Amatya, et al.
JAMA Oncology
|
January 6, 2022
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database
Mitchell S Anscher, Shaily Arora, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Melanie Royce, Christy Osgood, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
William F Maguire, Daniel Lee, Chana Weinstock, et al.
The Oncologist
|
December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
Sandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary
Paul G Kluetz, Yang-Min Ning, V Ellen Maher, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 118) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 29, 2020
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Suparna Wedam, Lola Fashoyin-Aje, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2022
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor
Vaibhav Kumar, Leslie Doros, Margaret Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
Preeti Narayan, Asma Dilawari, Christy Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
Mirat Shah, Christy L Osgood, Anup K Amatya, et al.
JAMA Oncology
|
January 6, 2022
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database
Mitchell S Anscher, Shaily Arora, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2022
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
Melanie Royce, Christy Osgood, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
William F Maguire, Daniel Lee, Chana Weinstock, et al.
The Oncologist
|
December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
Sandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 24, 2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary
Paul G Kluetz, Yang-Min Ning, V Ellen Maher, et al.
Page
of 12